Fig. 6

Targeting CD146 with the AA98 antibody suppresses eCM development and prevents cognitive impairment in artemether-treated eCM mice. a Survival analysis of eCM mice after a single treatment with the AA98 antibody on day 0, day 3, or day 5. b The percentages of parasitemia in eCM mice treated with antibodies (n = 6). c The clinical scores of eCM mice treated with antibodies (n = 10). d Survival analysis of eCM mice after AA98 antibody treatment on days 3, 5, 7 and 8 (n = 10). e The OD620 values of Evans blue in the brains of healthy mice treated with PBS and eCM mice treated with mIgG or AA98 antibodies (day 8) (n = 4). f The sequestration of pRBCs in the brains of healthy mice treated with PBS and eCM mice treated with mIgG or AA98 antibodies (day 8) (n = 3). White arrows indicate aggregated pRBCs. g CNS-infiltrated leukocytes from healthy mice treated with PBS and eCM mice treated with mIgG or AA98 antibodies (day 9) (n = 6). h The total alternations and successful alternations (%) in the three groups of mice in the Y maze test. The mean escape latency (i) and total distance to reach the platform (j) in the three groups of mice in the Morris water maze test. Each symbol represents a mouse. *p < 0.05, **p < 0.01, ***p < 0.001. The data are representative of at least three independent experiments